14 years of historical data (2011–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Can-Fite BioPharma Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14.2B | $12M | $9M | $17M | $24M | $21M | $9M | $25M | $24M | $33M | $34M |
| Enterprise Value | $14.2B | $7M | $5M | $14M | $20M | $13M | $7M | $21M | $21M | $25M | $17M |
| P/E Ratio → | -4.40 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 9999.00 | 17.54 | 12.62 | 20.58 | 27.88 | 27.87 | 4.65 | 6.42 | 28.49 | 194.42 | 203.45 |
| P/B Ratio | 6.34 | 2.17 | 1.50 | 3.73 | 1.65 | 3.50 | 3.87 | 8.13 | 7.88 | 8.51 | 3.21 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.54 | 6.91 | 16.98 | 22.88 | 17.12 | 3.36 | 5.47 | 24.35 | 146.56 | 100.76 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Can-Fite BioPharma Ltd. earns an operating margin of -1206.2%. Operating margins have expanded from -1246.4% to -1206.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -134.9% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -1206.2% | -1206.2% | -1103.0% | -1246.4% | -1505.5% | -1853.1% | -590.9% | -141.7% | -873.1% | -5093.7% | -3894.6% |
| Net Profit Margin | -1169.1% | -1169.1% | -1027.5% | -1255.9% | -1476.6% | -1892.9% | -621.3% | -172.0% | -588.2% | -4069.3% | -2912.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -134.9% | -134.9% | -142.5% | -107.9% | -123.1% | -339.2% | -462.7% | -216.5% | -143.4% | -96.3% | -55.5% |
| ROA | -82.5% | -82.5% | -79.2% | -68.9% | -84.6% | -163.2% | -156.6% | -83.3% | -55.2% | -49.7% | -34.5% |
| ROIC | -448.3% | -448.3% | -345.2% | -129.7% | -241.1% | — | — | — | — | — | — |
| ROCE | -108.1% | -108.1% | -111.1% | -83.1% | -99.6% | -214.9% | -246.7% | -99.6% | -107.7% | -73.5% | -52.3% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $104000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.68 | -0.65 | -0.30 | -1.35 | -1.07 | -1.20 | -1.15 | -2.09 | -1.62 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -580.71 | -580.71 | -585.36 | -631.04 | -713.44 | -36.53 | -26.80 | -300.78 | -263.42 | -315.66 | -11.37 |
Net cash position: cash ($5M) exceeds total debt ($104000)
Short-term solvency ratios and asset-utilisation metrics
Can-Fite BioPharma Ltd.'s current ratio of 4.38x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.66x to 4.38x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.38 | 4.38 | 4.90 | 3.66 | 7.35 | 7.41 | 2.18 | 2.53 | 3.82 | 4.04 | 9.86 |
| Quick Ratio | 4.38 | 4.38 | 4.90 | 3.68 | 7.37 | 7.41 | 2.40 | 2.53 | 5.66 | 4.04 | 10.21 |
| Cash Ratio | 3.84 | 3.84 | 4.42 | 3.19 | 7.01 | 6.57 | 0.84 | 1.25 | 1.95 | 3.24 | 9.52 |
| Asset Turnover | — | 0.07 | 0.07 | 0.09 | 0.04 | 0.08 | 0.25 | 0.48 | 0.11 | 0.02 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 41.70 | 38.32 | 21.18 | 20.54 | 8.61 | 114.42 | — | — | 47.02 | 137.37 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Can-Fite BioPharma Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $7M | $4M | $3M | $2M | $1M | $286366 | $129674 | $108417 | $92308 | $76510 |
Compare CANF with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CANFYou | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| KNSA | $3B | 59.3 | 41.0 | 133.6 | — | 11.4% | 23.6% | 17.1% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CANF stacks up against sector leader argenx SE.
Start ComparisonCan-Fite BioPharma Ltd.'s current P/E ratio is -4.4x. This places it at the 50th percentile of its historical range.
Can-Fite BioPharma Ltd.'s return on equity (ROE) is -134.9%. The historical average is -215.0%.
Based on historical data, Can-Fite BioPharma Ltd. is trading at a P/E of -4.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Can-Fite BioPharma Ltd. has 100.0% gross margin and -1206.2% operating margin.